-
World No.1 Sinner pulls out of Shanghai Masters to delay return
-
Ethiopia's Tigray rebels abandon regional capital as govt advances
-
Red Bull's Verstappen grabs pole position for Bahrain GP
-
Bulgaria's Tsar Samuel returns 'home' after 1,000 years
-
India beat Pakistan in blockbuster as golfer Kim wins 'crazy' gold
-
'Glad it's over': Kim powers to Games gold and military exemption
-
India beat arch-rivals Pakistan to win Asian Games cricket gold
-
After 11 World Cups, football finally comes home for one Indian fan
-
Ethiopia's Tigray rebels abandon regional capital as govt advances: journalist
-
Marc Marquez wins sprint at Japan MotoGP, Martin grabs pole
-
Tom Kim powers to Games gold and exemption from military service
-
Alcaraz fends off Arnaldi to reach Japan Open quarters
-
Split loyalties for Indian football fans at Brazil friendly
-
Antonelli tops times in final practice at Bahrain GP
-
India-Pakistan blockbuster brings cricket fever to Japan baseball field
-
Gauff digs deep to beat Osorio in China Open second round
-
Wong waiting on Rafa after winning Asian Games tennis gold
-
Fresh protests to hit Spain after housing measures defeated
-
With Russia next door and rising costs, Latvia goes to the polls
-
'He's here with me': Japan cycle queen dedicates gold to late brother
-
Penalty hero rues empty seats as Games hosts Japan win football gold
-
Japan Olympic chief says 'lot more' athletes at Games than expected
-
North Korea fires ballistic missile after Seoul's apology demand
-
Asian carmakers besting US rivals at home, China poised to strike
-
US regulator finds Boeing 737 MAX software bug 'not a safety concern'
-
Widgets & Web Offers All-Inclusive Investor Relations Websites for Public Companies, IPOs and SPACs
-
Ohtani 'managing' injuries as Dodgers launch MLB post-season
-
Adams named new US captain to 2030 World Cup
-
Botched US execution leaves murderer unconscious on ventilator: lawyers
-
China a better influence in Latin America than US: poll
-
Cornell rape case exposes sexual violence at US colleges
-
Judge pauses construction of border project in Texas national park
-
France held by Italy in Zidane's homecoming after Olise stunner
-
Belgium's De Bruyne fires double to sink Turkey, France held by Italy
-
Ethiopian pro-government militia claims Tigray airport as regional tensions spike
-
US jobs data boosts stocks as oil prices dip
-
Ohtani shaking off injuries as Dodgers launch MLB post-season
-
US Supreme Court to hear high-stakes climate case
-
Sea levels to rise in California as coastal wave surges up west coast
-
Trump expected to name intel chief Clayton as AI czar: reports
-
New rallies urged in France as protests disrupt over 730 schools
-
Argentina unveils passports-for-investment scheme
-
Djokovic survives China Open scare, Sabalenka starts strong
-
Brazil election debate chaos sparks censorship row
-
King Charles to evoke colonial 'darkest days' on Caribbean tour
-
England's Carse charged by cricket body over nightclub incident
-
Tesla shares jump after global car sales top estimates
-
Amazon vows $1 bn for data center towns, decries 'myths'
-
DR Congo Ebola outbreak killed more than 4,000: official figures
-
Oil prices drop on G7 fuel release, US jobs data boosts stocks
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC